Michael Jain

@MichaelDJain

Oncologist @moffittnews. Lymphoma CAR T/BMT. 🇨🇦 in Florida (does not miss the cold). Views my own.

Tampa, FL Joined August 2017

694 Following 1.2K Followers 1K Posts

Latest posts 5

Michael Jain @MichaelDJain Nov 2

Congratulations! Have been looking forward to this one for a while and enjoyed the preprint

Ash Alizadeh, MD/PhD 🇺🇸 Verified account @AshAlizadeh Nov 2

1/12 Excited to share our new study, out today in @NatureGenet on clonal hematopoiesis (CH) & cytopenias after CAR19 therapy. Led by Mark Hamilton and team with David Miklos and @max_diehn. How do blood-cell clones evolve after CAR T vs conventional cytotoxic Rx?
View quoted post on X

Michael Jain @MichaelDJain Oct 25

One of the best things about clinical medicine is the humor. Our CAR T program infuses all products as an outpatient. Now we are trying to manage grade 1 CRS as an outpatient as well. I found this picture taped to the wall: Treat and release (TNR) with my face on a fisherman! 😭

Michael Jain @MichaelDJain Oct 8

In @BloodAdvances we report on 56 patients with secondary MDS after CAR T cell therapy compared to @Ramikomrokji database of patients with tMN after auto transplant or standard chemo/XRT 🧵

pubmed.ncbi.nlm.nih.gov/42842872/

Michael Jain @MichaelDJain Oct 5

That is a spectacular HR for epcor with R-CHOP, I take back any previous skepticism.

Toby A. Eyre @tobyeyre82 Oct 5

EPCORE DLBCL-2 Positive RCT
Bispecifics to the 1L in DLBCL...
HR 0.49 #lymsm #DLBCL #Epcor

View quoted post on X

Michael Jain @MichaelDJain Oct 1

This excellent manuscript from @pbachi gives some answers about why allogeneic car t sometimes fails. Two categories: 1. Pre-existing patient immune responses that attack the donor CAR T and to me surprising 2. Effectors>stem-like (different from auto!). pubmed.ncbi.nlm.nih.gov/42788887/

pubmed.ncbi.nlm.nih.gov Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion - PubMed Allogeneic CAR T cells could overcome limitations of autologous therapies but are limited by immune rejection. We evaluated 11 patients with large B‑cell lymphoma treated with a single lot of...